Application of Monk Fruit Extract in Anti-pulmonary Fibrosis

A Luo Han Guo extract, pulmonary fibrosis technology, applied in medical preparations containing active ingredients, anti-inflammatory agents, drug combinations, etc., can solve problems such as no application report of Luo Han Guo extract, achieve clear activity of extract, cost Low, wide-ranging effects

Active Publication Date: 2020-06-16
GUANGXI XINHAI PHARM TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] So far, there is no report on the application of Luo Han Guo extract in anti-pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Monk Fruit Extract in Anti-pulmonary Fibrosis
  • Application of Monk Fruit Extract in Anti-pulmonary Fibrosis
  • Application of Monk Fruit Extract in Anti-pulmonary Fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 180

[0060] Example 1 80% Mogroside extract improves bleomycin-induced lung fibrosis in mice

[0061] Select 80% Mogrosides extract (Mogrosides>80%, product code MOV 09) produced by Guilin Laiyin Biotechnology Co., Ltd. to carry out the following in vivo Pharmacodynamic studies. Intratracheal injection of bleomycin to induce pulmonary fibrosis in mice is a method commonly used in the world, and it is similar to human pulmonary interstitial fibrosis.

[0062] When mogrosides are used for anti-pulmonary fibrosis, the dosage of experimental animals is 50mg-100mg / kg, which are respectively set as mogrosides-H and L groups. Mogrosides, also known as mogrosides, are the effective parts of the medicinal and edible plant Luo Han Guo. Mogroside total glycosides include Mogroside V (Mogroside V); Mogroside IVe (Mogroside IV); Mogroside IIIe (Mogroside IIeI); Mogroside II A2 (Mogroside II A2); Mogroside III A1 (Mogroside III A1); Mogroside IVa (Mogroside IVa); Mogroside VI (Mogroside VI); ...

Embodiment 2

[0085] Example 2 Mogroside IIIe improves bleomycin-induced mouse lung fibrosis

[0086] The above-mentioned mogroside IIIe was selected for the following in vivo pharmacodynamic studies. Intratracheal injection of bleomycin to induce pulmonary fibrosis in mice is a method commonly used in the world, and it is similar to human pulmonary interstitial fibrosis.

[0087] 2.1 Experimental method

[0088] ICR mice, male, weighing 25-30g, 100, provided by Yangzhou Comparative Medicine Center.

[0089] 20 mice were used as blank control group ( Figure 6 The control group in), the other 80 are used for making models, all the above-mentioned mice are anesthetized by intraperitoneal injection of 4% chloral hydrate, the injection volume is 10ml / kg, after the mice are anesthetized, the mice are fixed and the necks of the mice are disinfected Cut the mouse neck skin longitudinally with scissors to expose the trachea; inject a syringe into the trachea, inject normal saline into the mice ...

Embodiment 3

[0112] Example 3 Mogroside IVe improves mouse lung fibrosis induced by bleomycin

[0113] The above-mentioned mogroside IVe (formula IV) was selected for the following in vivo pharmacodynamic studies.

[0114] 3.1 Experimental method

[0115] ICR mice, male, weighing 25-30g, 100, provided by Yangzhou Comparative Medicine Center.

[0116] 20 mice were used as the blank control group, and the other 80 were used for modeling. All the above-mentioned mice were anesthetized by intraperitoneal injection of 4% chloral hydrate, and the injection volume was 10ml / kg. After the mice were anesthetized, the mice were fixed and sterilized Neck of the mouse: cut the skin of the neck of the mouse longitudinally with scissors, and bluntly tear the fascia and muscles longitudinally with tweezers to expose the trachea; inject a syringe into the trachea, inject normal saline into the mice in the blank control group, and inject normal saline into the other mice Bleomycin (5mg / kg); then the mouse...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a Siraitia grosvenorii extract, or an enzymolysate or hydrolysate thereof, and application in preparing a pharmaceutical drug or a health supplement for treating and / or preventing pulmonary fibrosis. The Siraitia grosvenorii extract has a total glycoside content of ≥ 50% by weight, preferably ≥ 80%. The Siraitia grosvenorii enzymolysate or hydrolysate comprises at least one or several of a mogroside IIIe, a mogroside IV, or a mogrol.

Description

technical field [0001] The invention belongs to the technical field of prevention and treatment of pulmonary fibrosis, and relates to the application of Luo Han Guo extract in the preparation of medicines and / or health care products for preventing and / or treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is caused by various pathogenic factors inside and outside the lungs, and is the result of a series of chronic lung injuries or the development of advanced diseases, which seriously endangers human health. The etiology of pulmonary fibrosis includes hereditary immune dysfunction, viral infection, drugs and chemicals, radiation, air pollution (smog, smoking, dust) and other factors. The pathophysiological process of pulmonary fibrosis is complex. In the early stage, pulmonary inflammation is the main factor. The alveolar wall is diffusely thickened, and a large number of inflammatory cells infiltrate. Destruction, loss of function. The clinic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61K36/42A61P11/00A61P29/00
CPCA61K36/42
Inventor 谢海峰张朝凤谢期林胡云岭
Owner GUANGXI XINHAI PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap